Type Condition

West Virginia

180 Clinical Paid Trials near West Virginia

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Bosutinib for Chronic Myeloid Leukemia

Pittsburgh, Pennsylvania
This trial tests bosutinib, a daily oral medication, in children with a type of leukemia. It aims to find a safe dose and see how well it works in those newly diagnosed or who haven't responded to other treatments. Bosutinib helps by blocking proteins that cancer cells need to grow. Bosutinib is a type of medication used for treating leukemia, especially in cases not responding to other treatments.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:1 - 17

60 Participants Needed

Tividenofusp Alfa for Hunter Syndrome

Pittsburgh, Pennsylvania
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:2 - 18
Sex:Male

47 Participants Needed

Dabrafenib + Trametinib + Hydroxychloroquine for Brain Tumor

Pittsburgh, Pennsylvania
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:1 - 30

57 Participants Needed

Viral Therapy + Pembrolizumab for Head and Neck Cancer

Charlottesville, Virginia
This trial is testing two new drugs, HB-201 and HB-202, which aim to help the immune system fight HPV 16-related cancers. It focuses on patients with advanced head and neck cancer who are also receiving a standard treatment called pembrolizumab. The goal is to see if these new drugs can improve the body's ability to combat cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

200 Participants Needed

Oral TP-3654 for Myelofibrosis

Charlottesville, Virginia
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

240 Participants Needed

CPI-0209 for Cancer and Lymphoma

Charlottesville, Virginia
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

275 Participants Needed

ARRY-614 + Immune Checkpoint Inhibitors for Cancer

Pittsburgh, Pennsylvania
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selected advanced solid tumors. The Phase II portion will estimate the efficacy of ARRY-614 in combination with either nivolumab or ARRY-614 + nivolumab+ipilimumab immunotherapy in patients with with NSCLC, HNSCC, melanoma and RCC and melanoma.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

70 Participants Needed

Ziftomenib for Relapsed/Refractory Acute Myeloid Leukemia

Pittsburgh, Pennsylvania
This trial is testing ziftomenib, a new drug, in patients with difficult-to-treat acute myeloid leukemia (AML). The drug works by blocking a protein interaction that cancer cells need to grow.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

263 Participants Needed

Gene Therapy for Fabry Disease

Pittsburgh, Pennsylvania
This trial tests ST-920, a treatment using a virus to deliver a gene that helps produce an important enzyme in patients with Fabry disease. The goal is to help these patients by continuously making the enzyme to reduce harmful substances in their bodies. ST-920 is a gene therapy treatment for Fabry disease, which aims to deliver a gene to produce the enzyme alpha-galactosidase A, addressing the enzyme deficiency central to the disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

34 Participants Needed

Niraparib + Standard Therapy for Prostate Cancer

Morgantown, West Virginia
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or returning. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding niraparib to the usual care may lower the chance of prostate cancer growing or returning.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Male

22 Participants Needed

Chemo-Radiation for Glioblastoma

Pittsburgh, Pennsylvania
This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

2 Participants Needed

CX-4945 for Medulloblastoma

Pittsburgh, Pennsylvania
This trial tests an oral drug called CX-4945 for patients with a recurring type of brain tumor. The drug aims to block a protein that helps cancer cells grow. The study will determine the best dose and check for side effects. CX-4945 has shown promising results in other types of cancer and may be developed as a new therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:3+

66 Participants Needed

Telaglenastat + Osimertinib for Non-Small Cell Lung Cancer

Charlottesville, Virginia
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene. Telaglenastat hydrochloride and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

22 Participants Needed

Cromoglicate for Schizophrenia

Pittsburgh, Pennsylvania
This trial tests a drug used for asthma and allergies on schizophrenia patients who don't fully respond to standard treatments. The drug may help by protecting the brain and targeting specific brain proteins. The drug has been used for years in treating asthma and allergies, showing effectiveness in stabilizing certain cells in the body and reducing the need for other medications.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

160 Participants Needed

Quizartinib for Acute Myeloid Leukemia

Pittsburgh, Pennsylvania
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:1 - 21

65 Participants Needed

Navtemadlin +/− Immunotherapy for Skin Cancer

Pittsburgh, Pennsylvania
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

115 Participants Needed

Tisotumab Vedotin Combinations for Cervical Cancer

Roanoke, Virginia
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer. The trial consists of two-parts a dose escalation part and an expansion part. The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) of the combinations have been determined in the dose escalation part.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female

214 Participants Needed

T Cell-Depleted Stem Cell Transplant for Leukemia

Pittsburgh, Pennsylvania
This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 26

68 Participants Needed

Chemo-Immunotherapy for Recurrent Ovarian Cancer

Pittsburgh, Pennsylvania
This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with recurrent platinum-sensitive ovarian cancer (OC).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female

24 Participants Needed

IMA203/IMA203CD8 + Nivolumab for Cancer

Pittsburgh, Pennsylvania
The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

375 Participants Needed

Why Other Patients Applied

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Immunotherapy + Radiation for Gastroesophageal Cancer

Pittsburgh, Pennsylvania
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

21 Participants Needed

Nivolumab + Radiosurgery for Recurrent Meningioma

Charlottesville, Virginia
This trial studies how well nivolumab and stereotactic radiosurgery, with or without ipilimumab, work in treating patients whose grade II-III meningioma has returned. The treatment aims to boost the immune system to fight cancer and use precise radiation to shrink the tumor. Nivolumab and ipilimumab are immune checkpoint inhibitors that have shown promise in treating various cancers, including brain metastases from melanoma.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

38 Participants Needed

Cabozantinib + Durvalumab +/- Tremelimumab for Gastrointestinal Cancers

Pittsburgh, Pennsylvania
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies. Finding effective novel therapies for patients with advanced gastric cancer and other GI malignancies is an area of great unmet need. The investigators believe that modulating the tumor microenvironment with biologic agents like cabozantinib will have synergistic effect when combined with checkpoint-based immunotherapeutics like durvalumab in this patient population. This is a phase I/II, open label, multi-cohort trial looking at safety, tolerability and efficacy endpoints.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

117 Participants Needed

MCLA-158 for Solid Cancers

Roanoke, Virginia
This trial is testing a new drug called MCLA-158 to see if it can help treat certain cancers by blocking a protein that helps cancer cells grow. It focuses on patients with cancers that rely on this protein, like colorectal and head and neck cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

523 Participants Needed

Lung and Bone Marrow Transplant for Pulmonary Fibrosis

Pittsburgh, Pennsylvania
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 60

8 Participants Needed

JCAR017 for Chronic Leukemia or Lymphoma

Pittsburgh, Pennsylvania
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

320 Participants Needed

HER2 BATs + Pembrolizumab for Breast Cancer

Charlottesville, Virginia
This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy. Study treatment includes a combination of 8 infusions of BATs using a previously established schedule and one to three infusions of PBZ (200 mg per dose). PBZ will be added to 8 infusions of BATs in 3 schedules: #1) after the 8th BATs infusion; #2) after the 4th and 8th BATs infusions; and then, #3) before the 1st and after the 4th and 8th BATs infusions.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Female

33 Participants Needed

EGFR BATs for Pancreatic Cancer

Charlottesville, Virginia
This protocol will confirm toxicities and estimate the clinical efficacy of combining anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given to patients with locally advanced or metastatic pancreatic cancer who have received at least one dose of first line chemotherapy and may have responding, stable or progressive disease. Phase Ib will confirm a safe dose of 8 infusions, given twice weekly, of EGFR-BATs in 3 to 6 subjects. The phase II portion of the trial will test the clinical efficacy of this dose in 22 patients (including those in Phase Ib).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

22 Participants Needed

TAK-788 for Non-Small Cell Lung Cancer

Charlottesville, Virginia
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

334 Participants Needed

ASTX660 for Cancer

Pittsburgh, Pennsylvania
This trial is testing ASTX660, a new drug for patients with advanced cancers who have no other treatment options. It works by blocking proteins that help cancer cells survive, making it easier to kill them.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

230 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in West Virginia pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in West Virginia work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in West Virginia 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in West Virginia is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in West Virginia several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in West Virginia?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in West Virginia?

Most recently, we added Adalimumab + Verapamil for Type 1 Diabetes, LevoCept for Birth Control and VLA15 Vaccine for Lyme Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

123 Clinical Trials near West Virginia

105 Clinical Paid Trials near Virginia

215 Clinical Paid Trials near Pittsburgh, PA

25 Schizophrenia Trials near West Palm Beach, FL

210 Clinical Paid Trials near Tampa, FL

44 Arthritis Trials near West Palm Beach, FL

218 Clinical Trials near Berkeley Heights, NJ

196 Clinical Trials near East Greenwich, RI

Top Clinical Trials near Virginia

Top Clinical Trials near Pittsburgh, PA

Top Clinical Trials near Bensalem, PA

Top Age-Related Macular Degeneration Clinical Trials

By Trial

HPV Vaccine Regimens for Human Papillomavirus

HPV Vaccine for Anal Cancer Prevention

NSAIDs for Lyme Arthritis

Trastuzumab Deruxtecan + Rilvegostomig/Pembrolizumab for Endometrial Cancer

Sun Protection for Skin Cancer Prevention

AL8326 for Small Cell Lung Cancer

Gardasil9 Vaccine for Human Papillomavirus

CRISPR Therapy (CTX001) for Thalassemia

Group Psychotherapy for Loneliness

Belantamab Mafodotin + SoC for Multiple Myeloma

Peer Navigation + Kidney Transplant Fast Track for Improving Access to Kidney Transplants in Minority Populations

Nivolumab for Esophageal Cancer

Related Searches

Top Alzheimers-disease Clinical Trials near Phoenix, AZ

Top Alzheimers-disease Clinical Trials near Raleigh, NC

Personal Health Library App for Formerly Incarcerated Individuals

EGFR BATs for Pancreatic Cancer

Catheter Sclerotherapy for Abdominal Abscess

PEACE App Intervention for Suicide Prevention in Veterans

Atibuclimab for Heart Attack

Sacituzumab Govitecan for Endometrial Cancer

Cabozantinib +/− Atezolizumab for Advanced Kidney Cancer

CRX100 for Solid Cancers

Robotic Waterjet Treatment for Prostate Cancer

Linvoseltamab for Multiple Myeloma

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial